Jeff Jones
Stock Analyst at Oppenheimer
(0.95)
# 3,573
Out of 4,712 analysts
78
Total ratings
22.86%
Success rate
-12.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jeff Jones
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLRB Cellectar Biosciences | Downgrades: Perform | n/a | $0.25 | - | 5 | Dec 11, 2024 | |
| CATX Perspective Therapeutics | Maintains: Outperform | $22 → $16 | $3.25 | +392.31% | 7 | Nov 22, 2024 | |
| EVH Evolent Health | Maintains: Outperform | $34 → $28 | $11.27 | +148.45% | 3 | Nov 18, 2024 | |
| YMAB Y-mAbs Therapeutics | Initiates: Outperform | $23 | $8.15 | +182.21% | 1 | Nov 18, 2024 | |
| CMMB Chemomab Therapeutics | Reiterates: Outperform | $13 → $11 | $1.71 | +542.11% | 7 | Nov 15, 2024 | |
| CRVS Corvus Pharmaceuticals | Reiterates: Outperform | $8 → $14 | $4.90 | +185.71% | 3 | Nov 13, 2024 | |
| VTYX Ventyx Biosciences | Reiterates: Outperform | $10 → $9 | $2.27 | +296.48% | 10 | Nov 8, 2024 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $52 → $56 | $40.82 | +37.19% | 4 | Sep 27, 2024 | |
| AVBP ArriVent BioPharma | Reiterates: Outperform | $35 → $39 | $26.63 | +46.45% | 2 | Sep 10, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $87 → $89 | $28.66 | +210.54% | 1 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $45 | $13.49 | +233.58% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $88 | $13.17 | +568.19% | 8 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $0.96 | - | 4 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $21 | $2.32 | +805.17% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.36 | - | 3 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $120 | $0.32 | +37,683.38% | 3 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.47 | +920.41% | 5 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $75 | $1.82 | +4,020.88% | 2 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $110 | $0.89 | +12,194.62% | 2 | Nov 17, 2022 |
Cellectar Biosciences
Dec 11, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.25
Upside: -
Perspective Therapeutics
Nov 22, 2024
Maintains: Outperform
Price Target: $22 → $16
Current: $3.25
Upside: +392.31%
Evolent Health
Nov 18, 2024
Maintains: Outperform
Price Target: $34 → $28
Current: $11.27
Upside: +148.45%
Y-mAbs Therapeutics
Nov 18, 2024
Initiates: Outperform
Price Target: $23
Current: $8.15
Upside: +182.21%
Chemomab Therapeutics
Nov 15, 2024
Reiterates: Outperform
Price Target: $13 → $11
Current: $1.71
Upside: +542.11%
Corvus Pharmaceuticals
Nov 13, 2024
Reiterates: Outperform
Price Target: $8 → $14
Current: $4.90
Upside: +185.71%
Ventyx Biosciences
Nov 8, 2024
Reiterates: Outperform
Price Target: $10 → $9
Current: $2.27
Upside: +296.48%
Kymera Therapeutics
Sep 27, 2024
Maintains: Outperform
Price Target: $52 → $56
Current: $40.82
Upside: +37.19%
ArriVent BioPharma
Sep 10, 2024
Reiterates: Outperform
Price Target: $35 → $39
Current: $26.63
Upside: +46.45%
Immunocore Holdings
Aug 9, 2024
Reiterates: Outperform
Price Target: $87 → $89
Current: $28.66
Upside: +210.54%
Aug 8, 2024
Maintains: Outperform
Price Target: $48 → $45
Current: $13.49
Upside: +233.58%
Aug 7, 2024
Maintains: Outperform
Price Target: $80 → $88
Current: $13.17
Upside: +568.19%
Jun 7, 2024
Downgrades: Perform
Price Target: n/a
Current: $0.96
Upside: -
May 10, 2024
Maintains: Outperform
Price Target: $16 → $21
Current: $2.32
Upside: +805.17%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.36
Upside: -
May 25, 2023
Maintains: Outperform
Price Target: $120
Current: $0.32
Upside: +37,683.38%
May 11, 2023
Reiterates: Outperform
Price Target: $15
Current: $1.47
Upside: +920.41%
Mar 24, 2023
Reiterates: Outperform
Price Target: $75
Current: $1.82
Upside: +4,020.88%
Nov 17, 2022
Maintains: Outperform
Price Target: $160 → $110
Current: $0.89
Upside: +12,194.62%